Compare PW & SHPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PW | SHPH |
|---|---|---|
| Founded | 1967 | 2012 |
| Country | United States | United States |
| Employees | 2 | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.1M | 1.9M |
| IPO Year | N/A | 2022 |
| Metric | PW | SHPH |
|---|---|---|
| Price | $9.20 | $3.19 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 6.5K | ★ 2.3M |
| Earning Date | 05-13-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.50 | $0.38 |
| 52 Week High | $12.92 | $6.15 |
| Indicator | PW | SHPH |
|---|---|---|
| Relative Strength Index (RSI) | 56.37 | 51.57 |
| Support Level | $8.85 | $3.10 |
| Resistance Level | $11.62 | $3.56 |
| Average True Range (ATR) | 0.58 | 0.51 |
| MACD | -0.30 | -0.11 |
| Stochastic Oscillator | 20.83 | 20.08 |
Power REIT is an internally-managed real estate investment trust that owns a portfolio of real estate assets related to transportation, energy infrastructure and Controlled Environment Agriculture in the United States. Its assets consisted of approximately 112 miles of railroad infrastructure and related real estate which is owned by its subsidiary, approximately 447 acres of fee simple land leased to a utility scale solar power generating project with an aggregate generating capacity of approximately 82 Megawatts and approximately 82 acres of land with approximately 357,000 square feet of CEA properties in the form of greenhouses. The company invested in greenhouses for state-licensed cannabis and food cultivation.
Shuttle Pharmaceuticals Holdings Inc is a clinical-stage pharmaceutical company leveraging its proprietary technology to develop novel therapies designed to cure cancers. The company has one operating segment with a focus on the development of novel drug therapies, including cancer therapies, extending new applications of radiation therapy, and other drug development, including through the use of the Molecule.ai platform by the company as well as licensing the right to use Molecuile.ai to others. The company's goal is to extend the benefits of cancer treatments with surgery, radiation therapy, chemotherapy and immunotherapy. Radiation therapy (RT) is one of the effective modalities for treating cancers. Its pipeline includes: Ropidoxuridine, HDAC Inhibitors, PSMA-B, and PC-Rad Test.